H. Res. 960 is a House resolution that expresses support for designating November 2025 as "National Lung Cancer Awareness Month" and for related observances (a women’s lung cancer awareness week and a lung cancer screening day).
The resolution urges increased public education, screening awareness, research, and attention to lung cancer among groups that face higher risk or poorer access to care.
The measure is purely symbolic: it contains no authorizations of funding, no regulatory mandates, and does not change eligibility or coverage rules. Its practical effect would be to signal congressional attention and to encourage public-health organizations, health systems, and advocacy groups to prioritize outreach and screening promotion for high‑risk and underserved populations.
At a Glance
What It Does
The resolution records a series of factual findings about lung cancer incidence, mortality, disparities, screening gaps, and research advances, and formally expresses support for naming November 2025 as National Lung Cancer Awareness Month plus complementary observances. It directs no agencies to act and does not appropriate funds; it instead encourages public awareness and educational activities.
Who It Affects
The resolution most directly speaks to public‑health agencies, the Department of Veterans Affairs, clinicians and cancer centers, advocacy groups, and community organizations that run screening and outreach programs. High‑risk populations cited include veterans, racial and ethnic minorities, women who never smoked, and people eligible for low‑dose CT screening.
Why It Matters
Symbolic congressional support can amplify campaigns, help advocacy groups secure attention or private funding, and shape administrative priorities without legislation. It also crystallizes a set of priorities—early detection, reducing stigma, addressing disparities, and expanding access to biomarker testing—that stakeholders can use to justify programmatic activity.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
H. Res. 960 is a straightforward, nonbinding House resolution.
Its text compiles findings about lung cancer in the United States—incidence, mortality, risk factors, screening shortfalls, disparities affecting veterans and people of color, and recent research advances—and then resolves that the House supports declaring November 2025 National Lung Cancer Awareness Month, a National Women’s Lung Cancer Awareness Week, and a National Lung Cancer Screening Day. The resolution also promotes awareness, education, research, and efforts to mitigate risk factors and expand screening and treatment.
The bill includes numerous factual statements from the record: projected 2025 diagnoses and deaths; the role of cigarette smoking and secondhand smoke; a rising share of diagnoses among people who never smoked (with women who never smoked at higher risk than men who never smoked); and survival differences depending on stage at diagnosis. It cites an estimate that approximately 14.5 million people met screening recommendations in 2021, but only 16 percent of high‑risk individuals underwent screening, and that veterans—despite elevated risk—have very low screening uptake (less than 3 percent of eligible veterans screened).Practically, the resolution does not create new programs or change health‑care reimbursement.
Its leverage comes through persuasion: federal agencies, state and local health departments, the VA, advocacy groups, and private funders can point to the congressional statement when prioritizing outreach, convening partners, or seeking grants. Because the text highlights barriers—geographic access, transportation, unfamiliarity with low‑dose CT, stigma, and uneven access to biomarker testing—stakeholders that run screening programs can use the resolution as a policy rationale for expanding mobile screening, telehealth triage, community outreach, or targeted education campaigns.Finally, the resolution spotlights research progress (biomarkers, immunotherapies, targeted therapies) and access problems for advanced diagnostics.
That focus may encourage health systems and labs to prioritize equitable roll‑out of biomarker testing and could be cited in advocacy for funding or regulatory attention, even though the resolution itself does not require any such action.
The Five Things You Need to Know
The resolution designates November 2025 as "National Lung Cancer Awareness Month," and separately supports a "National Women’s Lung Cancer Awareness Week" and a "National Lung Cancer Screening Day.", It cites projected 2025 figures of 226,650 new lung cancer diagnoses and 124,730 deaths (about 340 deaths per day).
The bill highlights that cigarette smoking directly caused an estimated 109,100 of the 2025 lung cancer deaths, and that secondhand smoke causes over 7,300 lung cancer deaths annually in adults who do not smoke.
The resolution notes screening metrics: roughly 14.5 million people were estimated to be recommended for lung cancer screening in 2021, yet only 16 percent of high‑risk individuals undergo screening.
It calls out veterans specifically—stating veterans are ~25 percent more likely to develop lung cancer and that less than 3 percent of eligible veterans get screened—while also pointing to racial disparities in incidence and later diagnosis.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Record of facts about incidence, mortality, risk, screening gaps, and disparities
This section assembles the bill’s evidentiary record: national incidence and mortality estimates for 2025, lifetime risk statistics, the proportion of deaths attributable to smoking and secondhand smoke, the share of cases in never‑smokers, gender and racial disparities, veteran risk and low screening rates, survival differences by stage, and barriers to screening and biomarker access. Practically, these findings frame the policy priorities the resolution endorses—early detection, stigma reduction, access to diagnostics—and provide talking points stakeholders can use when seeking resources or partnerships.
Formal support for month/week/day observances
These clauses officially express the House’s support for naming November 2025 as National Lung Cancer Awareness Month, for a National Women’s Lung Cancer Awareness Week, and for a National Lung Cancer Screening Day. Because this is a simple resolution, the language creates no binding obligations; its immediate effect is to register congressional attention that advocacy groups or agencies can invoke when organizing events or awareness campaigns.
Promotion of awareness, research, and observance
This part directs congressional support to a set of goals—education about risk mitigation, screening, treatment, and attention to lung cancer in minorities and never‑smokers—and encourages people to observe the month with educational activities. The clause is permissive and hortatory, not prescriptive: it encourages but does not require agencies or payers to act, which means operational responses (expanded screening sites, outreach to veterans, or biomarker testing programs) would depend on separate administrative or funding decisions.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- High‑risk individuals (current and former smokers): Greater public awareness and targeted screening campaigns could increase early detection for people eligible for low‑dose CT, improving prognosis for those diagnosed at a localized stage.
- Veterans: The resolution explicitly highlights veteran risk and low screening uptake, which advocacy groups and the VA can use to justify focused outreach and targeted screening initiatives for this population.
- Advocacy and patient‑facing organizations: Congressional backing provides a visibility boost that organizations can leverage to secure media attention, private grants, and partnerships for education and screening drives.
- Researchers and diagnostic labs: The emphasis on biomarkers and new therapies amplifies demand for equitable access to molecular testing and may support fundraising or pilot programs to expand diagnostic capacity in underserved areas.
- Public‑health departments and community health centers: The resolution offers a public rationale to mobilize local campaigns, partnerships, and volunteer efforts aimed at reducing screening barriers (e.g., transportation, awareness).
Who Bears the Cost
- Federal and state health agencies (indirectly): While the resolution authorizes no spending, agencies that respond to heightened demand may reallocate staff time and program resources toward outreach and coordination without additional appropriations.
- Department of Veterans Affairs: If the VA expands screening outreach in response to the resolution and stakeholder pressure, it may incur operational costs (outreach, transportation assistance, scheduling, follow‑up) to reach eligible veterans.
- Health systems and imaging centers: A successful awareness campaign could raise demand for low‑dose CT screening and downstream diagnostics, creating capacity pressures and potential short‑term costs for triage, follow‑up imaging, and procedures.
- Clinical laboratories: Calls to expand biomarker testing may increase demand for specialized assays and staffing, with costs borne initially by hospitals, labs, or payers unless separate reimbursement changes occur.
- Insurers (potentially): Insurers could face more screening and diagnostic claims if awareness campaigns increase utilization, although the resolution does not compel coverage changes.
Key Issues
The Core Tension
The central dilemma is this: the resolution aims to save lives by elevating early detection and directing attention to underserved groups, but it is purely hortatory—raising public demand and expectations without allocating funds or changing coverage rules may produce operational strain, inconsistent geographic impact, and limited progress unless matched by concrete funding or administrative action.
The resolution balances symbolic pressure with no direct funding or mandates, which creates implementation ambiguity. Stakeholders who want action must translate the rhetorical support into programs, grant requests, or administrative prioritization; absent follow‑on funding or regulatory change, the resolution’s ability to close screening gaps or improve biomarker access is limited.
That gap raises the prospect of heightened expectations—public campaigns that increase demand for screening without parallel investments in capacity, transportation support, or provider availability.
There are clinical trade‑offs the resolution does not resolve. Expanding screening can improve early detection and survival for some, but it also increases false positives, incidental findings, and overdiagnosis that strain diagnostic pathways and patient counseling.
The text highlights disparities (race, veteran status, never‑smoker diagnosis rates) and access barriers (geography, transportation, unfamiliarity), but it does not set priorities or funding mechanisms to address which barriers should be tackled first, nor does it provide metrics for measuring impact. Finally, while the resolution calls attention to biomarker testing and novel therapies, equitable access to those tests requires payer coverage, lab capacity, and workforce investment beyond the scope of a House resolution.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.